Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Retigabine, A Novel Anti-Convulsant, Enhances Activation of KCNQ2/Q3 Potassium Channels

Alan D. Wickenden, Weifeng Yu, Anrou Zou, Tim Jegla and P. Kay Wagoner
Molecular Pharmacology September 2000, 58 (3) 591-600; DOI: https://doi.org/10.1124/mol.58.3.591
Alan D. Wickenden
ICAgen Inc., Durham, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weifeng Yu
ICAgen Inc., Durham, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anrou Zou
ICAgen Inc., Durham, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Jegla
ICAgen Inc., Durham, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Kay Wagoner
ICAgen Inc., Durham, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 58 no. 3 591-600
DOI 
https://doi.org/10.1124/mol.58.3.591
PubMed 
10953053

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Received December 3, 1999
  • Accepted June 5, 2000
  • Published online September 1, 2000.

Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Alan D. Wickenden,
  2. Weifeng Yu,
  3. Anrou Zou,
  4. Tim Jegla, and
  5. P. Kay Wagoner
  1. ICAgen Inc., Durham, North Carolina
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2000 to August 2022

AbstractFullPdf
Aug 2000343657
Sep 2000213746
Oct 200032943
Nov 20004219
Dec 200031611
Jan 200141520
Feb 200122622
Mar 200142919
Apr 200161519
May 200101814
Jun 20012129
Jul 20013106
Aug 20011125
Sep 20012615
Oct 2001166
Nov 200101016
Dec 2001059
Jan 2002178
Feb 2002118
Mar 20020921
Apr 200201517
May 20021107
Jun 20021612
Jul 20022129
Aug 200221313
Sep 200261516
Oct 200201413
Nov 200201414
Dec 2002182
Jan 2003388
Feb 200361015
Mar 200321618
Apr 2003199
May 200311112
Jun 200321111
Jul 20037126
Aug 2003282420
Sep 2003102815
Oct 2003184323
Nov 2003204128
Dec 2003272818
Jan 2004203117
Feb 2004172913
Mar 2004193420
Apr 2004132111
May 2004173417
Jun 200417348
Jul 2004224014
Aug 200493912
Sep 2004196223
Oct 200425647
Nov 2004336822
Dec 200415307
Jan 2005155912
Feb 200516176
Mar 2005172312
Apr 200541610
May 2005102013
Jun 2005102513
Jul 200542412
Aug 2005132515
Sep 200519128
Oct 200513167
Nov 2005202312
Dec 200591912
Jan 2006153713
Feb 200664220
Mar 20067204
Apr 20064188
May 2006121613
Jun 20066199
Jul 200651610
Aug 200641515
Sep 20064154
Oct 200671313
Nov 20064166
Dec 200671521
Jan 200711431
Feb 200772712
Mar 2007112428
Apr 200772713
May 20073145
Jun 200771515
Jul 200762436
Aug 200732044
Sep 200762251
Oct 2007351957
Nov 2007132845
Dec 200752141
Jan 200891946
Feb 200821142
Mar 2008161953
Apr 2008101829
May 200892222
Jun 2008144425
Jul 200882028
Aug 200881312
Sep 2008151718
Oct 2008172334
Nov 200841021
Dec 200891313
Jan 200981320
Feb 2009141525
Mar 2009151415
Apr 200992023
May 200942815
Jun 200952114
Jul 200982014
Aug 200991413
Sep 2009131310
Oct 20091168
Nov 200962319
Dec 2009101115
Jan 201091112
Feb 2010101314
Mar 201081110
Apr 201061513
May 20103135
Jun 201061313
Jul 2010172216
Aug 201061512
Sep 2010191116
Oct 201061115
Nov 201061213
Dec 2010122020
Jan 201151513
Feb 201191514
Mar 201192215
Apr 201172626
May 2011111819
Jun 201161820
Jul 2011151624
Aug 2011101516
Sep 2011161819
Oct 2011212523
Nov 2011143635
Dec 2011143633
Jan 2012141423
Feb 2012112035
Mar 201291627
Apr 2012202535
May 2012142334
Jun 2012141831
Jul 201282829
Aug 201271922
Sep 2012153229
Oct 2012202838
Nov 2012122249
Dec 2012151228
Jan 2013212427
Feb 2013212641
Mar 2013121833
Apr 2013201444
May 2013202136
Jun 20137928
Jul 201361037
Aug 201315126
Sep 2013141516
Oct 2013291232
Nov 2013211633
Dec 201322514
Jan 2014181921
Feb 2014132530
Mar 201413923
Apr 2014101329
May 2014221529
Jun 201414922
Jul 2014121423
Aug 201413424
Sep 2014111313
Oct 2014342217
Nov 2014352150
Dec 2014251216
Jan 2015121110
Feb 201515810
Mar 2015171715
Apr 2015171619
May 2015171919
Jun 2015161319
Jul 201516169
Aug 201513188
Sep 2015121316
Oct 2015121117
Nov 2015102217
Dec 2015101415
Jan 2016131220
Feb 2016361317
Mar 201620617
Apr 2016241019
May 2016321925
Jun 201618718
Jul 2016131317
Aug 201615623
Sep 2016141724
Oct 2016102318
Nov 201634623
Dec 201664312
Jan 201723216
Feb 201743813
Mar 201711267
Apr 201742919
May 20172217
Jun 201701319
Jul 20174146
Aug 201722612
Sep 201732611
Oct 201783721
Nov 201723912
Dec 201711219
Jan 20187267
Feb 201852922
Mar 201852911
Apr 201834315
May 201862918
Jun 201812216
Jul 201851712
Aug 20180176
Sep 201833613
Oct 2018104717
Nov 201852220
Dec 2018631023
Jan 201950113
Feb 20192121
Mar 20191721
Apr 201920107
May 20192542
Jun 20194153
Jul 2019952
Aug 20194364
Sep 20193975
Oct 20193897
Nov 201958137
Dec 20193641
Jan 20201752
Feb 20205478
Mar 20202073
Apr 20203052
May 20203481
Jun 20202111
Jul 20203151
Aug 20202841
Sep 202028113
Oct 20203231
Nov 20202182
Dec 202037105
Jan 202132123
Feb 202145103
Mar 202134116
Apr 202130229
May 202138135
Jun 202124811
Jul 20212031
Aug 202127140
Sep 20213572
Oct 20213497
Nov 20213753
Dec 20213561
Jan 20223721
Feb 20225344
Mar 20222782
Apr 20223392
May 202242106
Jun 20221851
Jul 202239113
Aug 20221400

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 58 (3)
Molecular Pharmacology
Vol. 58, Issue 3
1 Sep 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Retigabine, A Novel Anti-Convulsant, Enhances Activation of KCNQ2/Q3 Potassium Channels
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Retigabine, A Novel Anti-Convulsant, Enhances Activation of KCNQ2/Q3 Potassium Channels

Alan D. Wickenden, Weifeng Yu, Anrou Zou, Tim Jegla and P. Kay Wagoner
Molecular Pharmacology September 1, 2000, 58 (3) 591-600; DOI: https://doi.org/10.1124/mol.58.3.591

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Retigabine, A Novel Anti-Convulsant, Enhances Activation of KCNQ2/Q3 Potassium Channels

Alan D. Wickenden, Weifeng Yu, Anrou Zou, Tim Jegla and P. Kay Wagoner
Molecular Pharmacology September 1, 2000, 58 (3) 591-600; DOI: https://doi.org/10.1124/mol.58.3.591
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • α-Conotoxin Binding Site on the GABAB Receptor
  • Upacicalcet binds to the amino acid binding site of CaSR
  • Characterization of GRD and LCCH3 from Human Louse
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics